- Previous Close
1.2750 - Open
1.2550 - Bid 1.2400 x --
- Ask 1.2750 x --
- Day's Range
1.2150 - 1.2650 - 52 Week Range
1.1000 - 2.5000 - Volume
43,847 - Avg. Volume
166,909 - Market Cap (intraday)
141.7M - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 1, 2023
- 1y Target Est
2.70
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
www.cyclomedica.com/company/cyclopharm/Recent News: CYC.AX
View More
Performance Overview: CYC.AX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYC.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYC.AX
View MoreValuation Measures
Market Cap
137.81M
Enterprise Value
125.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.63
Price/Book (mrq)
3.23
Enterprise Value/Revenue
4.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-47.87%
Return on Assets (ttm)
-16.80%
Return on Equity (ttm)
-35.20%
Revenue (ttm)
27.57M
Net Income Avi to Common (ttm)
-13.2M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
20.57M
Total Debt/Equity (mrq)
19.39%
Levered Free Cash Flow (ttm)
-10.21M